secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001493152-26-005463
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharmaceuticals voluntarily delisting from Nasdaq, terminating SEC registration effective Feb 27, 2026
--------------------------------------------------------------------------------

- Board approved voluntary delisting from Nasdaq and deregistration with SEC on Feb 5, 2026; Nasdaq notified Feb 6.
- Form 25 to be filed on or about Feb 17; delisting expected effective Feb 27, 2026.
- Form 15 to be filed on or about Feb 27 certifying fewer than 300 record holders, suspending SEC reporting.
- Company is in compliance with Nasdaq rules; delisting decision based on cost of public company burdens outweighing benefits.
- Following delisting, trading will occur only in privately negotiated sales or on the OTC market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315226005463/0001493152-26-005463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315226005463/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer